Cologuard(R) Gains FDA Approval For Use In Younger Americans, Ages 45 To 49

Stool DNA test offers a sensitive, noninvasive, at-home option to screen for colorectal cancer, second deadliest cancer in U.S. MADISON, Wis., Sept. 23, 2019 -- (Healthcare Sales & Marketing Network) -- Exact Sciences Corp. (NASDAQ: EXAS) announced tod... Diagnostics, Oncology, FDA Exact Sciences, Cologuard, colorectal cancer, cancer screening
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news